Related Experiment Video

Updated: May 10, 2026

In vitro Methylation Assay to Study Protein Arginine Methylation
10:01

In vitro Methylation Assay to Study Protein Arginine Methylation

Published on: October 5, 2014

15.4K

Use of Protein Arginine Methyltransferase Inhibitors in Gliomas

Emirhan Harbi1, Christopher E Mason2

  • 1Faculty of Engineering and Natural Sciences, Bahcesehir University, Istanbul, Turkey.

JCO Precision Oncology
|August 27, 2025
PubMed

Insights

Protein arginine methyltransferases (PRMTs) are key in glioma development and therapy resistance. PRMT inhibitors show promise for treating gliomas by disrupting tumor growth and enhancing treatment sensitivity.

Area of Science:

  • Neuro-oncology
  • Epigenetics
  • Cancer Biology

Background:

  • Gliomas are primary central nervous system (CNS) tumors.
  • Protein arginine methyltransferases (PRMTs) regulate epigenetic processes crucial in cancer.
  • PRMTs are overexpressed in gliomas, correlating with tumor progression and therapeutic resistance.

Purpose of the Study:

  • To review the translational and clinical relevance of PRMT inhibitors in glioma subtypes.
  • To highlight the latest clinical developments and ongoing trials for PRMT inhibitors in gliomas.
  • To provide an updated synthesis of clinical data, discuss challenges, and suggest future directions for PRMT inhibitors in glioma therapy.

Main Methods:

  • Literature review focusing on preclinical and clinical studies of PRMT inhibitors in gliomas.
  • Synthesis of current clinical data on PRMT inhibitors across different glioma subtypes.
  • Analysis of challenges and opportunities in the clinical translation of PRMT inhibitors.

Main Results:

  • PRMTs play significant roles in DNA repair and cellular signaling pathways in gliomas.
  • Targeting PRMTs demonstrates preclinical efficacy in disrupting tumor growth and enhancing DNA damage.
  • PRMT inhibitors show potential to improve glioma sensitivity to radiotherapy and temozolomide.

Conclusions:

  • PRMT inhibitors represent a promising therapeutic strategy for various glioma subtypes.
  • Further clinical development and investigation are warranted to optimize the integration of PRMT inhibitors into glioma treatment protocols.
  • Addressing challenges in clinical translation is crucial for realizing the full potential of PRMT inhibitors in neuro-oncology.

More Related Videos

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.3K
Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

1.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.